Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,434 questions in 139 reviews · Kidney and Transplant
current versionsNo studies 504 · 20.7%Ungraded 40 · 1.6%Very low 611 · 25.1%Low 790 · 32.5%Moderate 414 · 17%High 75 · 3.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ravulizumab vs placebo or alternative treatment Adverse events · adults with aHUS Interventions for atypical haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | 58 participants | Very low |
Ravulizumab vs placebo or alternative treatment Meningococcal infection · adults with aHUS Interventions for atypical haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | 58 participants | Very low |
Eculizumab vs placebo or alternative treatment Requirement for KRT · children and adults with aHUS Interventions for atypical haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | 100 participants | Very low |
Eculizumab vs placebo or alternative treatment Disease remission · children and adults with aHUS Interventions for atypical haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | 100 participants | Very low |
Eculizumab vs placebo or alternative treatment Change in eGFR · children and adults with aHUS Interventions for atypical haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | 88 participants | Very low |
Eculizumab vs placebo or alternative treatment HRQoL · children and adults with aHUS Interventions for atypical haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | 100 participants | Very low |
Eculizumab vs placebo or alternative treatment Adverse events · children and adults with aHUS Interventions for atypical haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | 100 participants | Very low |
Eculizumab vs placebo or alternative treatment Meningococcal infection · children and adults with aHUS Interventions for atypical haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | 100 participants | Very low |
Ravulizumab vs placebo or alternative treatment Death · adults with aHUS Interventions for atypical haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | 58 participants | Very low |
Ravulizumab vs placebo or alternative treatment Requirement for KRT · adults with aHUS Interventions for atypical haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | 56 participants | Very low |
Intervention NR Bacteraemia up to 6 months · people with CKD Urgent‐start peritoneal dialysis versus haemodialysis for people with chronic kidney disease (2021) · Cochrane | RR 0.13 [0.04, 0.41] | 2 studies · 301 participants | Low |
Intervention NR Hospitalisation up to 6 months · people with CKD Urgent‐start peritoneal dialysis versus haemodialysis for people with chronic kidney disease (2021) · Cochrane | RR 1.18 [0.89, 1.55] | 1 study · 123 participants | Very low |
Intervention NR Peritonitis up to 6 months · people with CKD Urgent‐start peritoneal dialysis versus haemodialysis for people with chronic kidney disease (2021) · Cochrane | RR 1.78 [0.23, 13.62] | 2 studies · 301 participants | Very low |
Intervention NR Exit‐site or tunnel infection · people with CKD Urgent‐start peritoneal dialysis versus haemodialysis for people with chronic kidney disease (2021) · Cochrane | RR 3.99 [1.32, 12.05] | 1 study · 419 participants | Very low |
Intervention NR Exit‐site bleeding · people with CKD Urgent‐start peritoneal dialysis versus haemodialysis for people with chronic kidney disease (2021) · Cochrane | RR 0.12 [0.01, 2.33] | 1 study · 178 participants | Very low |
Intervention NR Catheter malfunction · people with CKD Urgent‐start peritoneal dialysis versus haemodialysis for people with chronic kidney disease (2021) · Cochrane | RR 0.26 [0.07, 0.91] | 2 studies · 597 participants | Very low |
Intervention NR Catheter re‐adjustment up to 60 months · people with CKD Urgent‐start peritoneal dialysis versus haemodialysis for people with chronic kidney disease (2021) · Cochrane | RR 0.13 [0, 18.61] | 2 studies · 225 participants | Very low |
Intervention NR Technique survival up to 6 months · people with CKD Urgent‐start peritoneal dialysis versus haemodialysis for people with chronic kidney disease (2021) · Cochrane | RR 1.18 [0.87, 1.61] | 1 study · 123 participants | Very low |
Intervention NR Home dialysis · people with CKD Urgent‐start peritoneal dialysis versus haemodialysis for people with chronic kidney disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Death (any cause) up to 24 months · people with CKD Urgent‐start peritoneal dialysis versus haemodialysis for people with chronic kidney disease (2021) · Cochrane | RR 0.68 [0.44, 1.07] | 5 studies · 820 participants | Very low |
Antibiotics vs no treatment Incidence of HUS · patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | RR 0.57 [0.11, 2.81] | 1 study · 47 participants | Very low |
Bovine colostrum vs placebo Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Synsorb Pk vs placebo Incidence of HUS · patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | RR 0.93 [0.39, 2.22] | 1 study · 353 participants | Very low |
Synsorb Pk vs placebo Adverse events · patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Synsorb Pk vs placebo Need for acute dialysis · patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Synsorb Pk vs placebo Neurological complications · patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Synsorb Pk vs placebo Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Urtoxazumab (3.0 mg/kg) vs placebo Incidence of HUS · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | RR 0.34 [0.01, 8.14] | 1 study · 71 participants | Very low |
Urtoxazumab (3.0 mg/kg) vs placebo Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | RR 1 [0.84, 1.18] | 1 study · 71 participants | Low |
Urtoxazumab (3.0 mg/kg) vs placebo Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | 1 study · 71 participants | Low |
Urtoxazumab (3.0 mg/kg) vs placebo Need for acute dialysis · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Antibiotics vs no treatment Adverse events · patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Urtoxazumab (3.0 mg/kg) vs placebo Neurological complications · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | RR 2.06 [0.2, 21.68] | 1 study · 71 participants | Very low |
Urtoxazumab (3.0 mg/kg) vs placebo Death (any cause) · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | RR 0.34 [0.01, 8.14] | 1 study · 71 participants | Very low |
Urtoxazumab (1.0 mg/kg) vs placebo Incidence of HUS · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | RR 0.95 [0.06, 14.59] | 1 study · 74 participants | Very low |
Urtoxazumab (1.0 mg/kg) vs placebo Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | RR 0.95 [0.79, 1.13] | 1 study · 74 participants | Low |
Urtoxazumab (1.0 mg/kg) vs placebo Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | 1 study · 74 participants | Low |
Urtoxazumab (1.0 mg/kg) vs placebo Need for acute dialysis · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Urtoxazumab (1.0 mg/kg) vs placebo Neurological complications · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | RR 2.84 [0.31, 26.08] | 1 study · 74 participants | Very low |
Urtoxazumab (1.0 mg/kg) vs placebo Death (any cause) · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | RR 0.95 [0.06, 14.59] | 1 study · 74 participants | Very low |
Antibiotics vs no treatment Need for acute dialysis · patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Antibiotics vs no treatment Neurological complications · patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Antibiotics vs no treatment Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Bovine colostrum vs placebo Incidence of HUS · patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | 1 study · 27 participants | Very low |
Bovine colostrum vs placebo Adverse events · patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | RR 0.92 [0.42, 2.03] | 1 study · 27 participants | Very low |
Bovine colostrum vs placebo Need for acute dialysis · patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Bovine colostrum vs placebo Neurological complications · patients with diarrhoea due to Shiga toxin‐producing E. coli Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome (2021) · Cochrane | no estimate extracted | NR | No studies |
Aldosterone antagonists (spironolactone or eplerenone) vs control (placebo or standard care) Death (any cause) · people with chronic kidney disease requiring dialysis Aldosterone antagonists for people with chronic kidney disease requiring dialysis (2021) · Cochrane | RR 0.45 [0.3, 0.67] | 9 studies · 1119 participants | Moderate |
Aldosterone antagonists (spironolactone or eplerenone) vs control (placebo or standard care) Death (cardiovascular) · people with chronic kidney disease requiring dialysis Aldosterone antagonists for people with chronic kidney disease requiring dialysis (2021) · Cochrane | RR 0.37 [0.22, 0.64] | 6 studies · 908 participants | Moderate |
Aldosterone antagonists (spironolactone or eplerenone) vs control (placebo or standard care) Cardiovascular and cerebrovascular morbidity · people with chronic kidney disease requiring dialysis Aldosterone antagonists for people with chronic kidney disease requiring dialysis (2021) · Cochrane | RR 0.38 [0.18, 0.76] | 3 studies · 328 participants | Moderate |